Rhythm Pharmaceuticals presents Phase 3 TRANSCEND trial data

Rhythm Pharmaceuticals (RYTM) announced the presentation of new data delivered by Rhythm and its partners at The Pediatric Endocrine Society Annual Meeting. “The data presented provide important longer-term insights into treatment response for pediatric patients treated with setmelanotide, including reductions across multiple weight-related measures,” said Jennifer Miller, professor of pediatrics, pediatric endocrinology, University of Florida College of Medicine. Pediatric patients with acquired hypothalamic obesity who received setmelanotide for up to 2.5 years achieved sustained reductions across multiple age-adjusted weight-related measures. Among pediatric participants who completed 2.5 years of treatment, mean changes from baseline included a 16.4% change in BMI. Furthermore, data from the Phase 3 TRANSCEND trial showed that after one year of treatment, 71.1% of pediatric patients treated with setmelanotide improved by at least one weight category.